Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DANAHER CORPORATION

(DHR)
  Report
Delayed Nyse  -  04:03:29 2023-01-26 pm EST
265.86 USD   +1.11%
01/26Insider Sell: Danaher
MT
01/25Cowen Adjusts Price Target on Danaher to $320 From $340, Maintains Outperform Rating
MT
01/25RBC Cuts Price Target on Danaher to $289 From $293, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher Corporation Enters Into Strategic Partnership with Duke University

11/10/2022 | 04:15pm EST

Danaher Corporation has entered strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. Danaher Beacons is a new initiative designed to access breakthrough science to create technologies and applications that will improve human health. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

Dr. Aravind Asokan, a synthetic virologist and Duke professor of surgery and biomedical engineering will lead the Danaher Beacon for Gene Therapy Innovation. The focus of this Beacon will be on product solutions that address bottlenecks impacting viral vector manufacturing yield and quality. The partnership began in late October 2022 and is expected to run for multiple years.


ę S&P Capital IQ 2022
All news about DANAHER CORPORATION
01/26Insider Sell: Danaher
MT
01/25Cowen Adjusts Price Target on Danaher to $320 From $340, Maintains Outperform Rating
MT
01/25RBC Cuts Price Target on Danaher to $289 From $293, Maintains Outperform Rating
MT
01/24Danaher Fourth-Quarter Results Top Views; Cuts COVID-19-Related Revenue From Sales Grow..
MT
01/24Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
MS
01/24Is the Fed losing its grip on investors?
MS
01/24Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday
MT
01/24Sector Update: Health Care
MT
01/24Barclays Adjusts Danaher Price Target to $290 From $277, Maintains Overweight Rating
MT
01/24Transcript : Danaher Corporation, Q4 2022 Earnings Call, Jan 24, 2023
CI
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2022 31 019 M - -
Net income 2022 6 496 M - -
Net Debt 2022 12 130 M - -
P/E ratio 2022 30,4x
Yield 2022 0,38%
Capitalization 194 B 194 B -
EV / Sales 2022 6,63x
EV / Sales 2023 6,57x
Nbr of Employees 81 000
Free-Float 74,6%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 265,86 $
Average target price 302,25 $
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose-Carlos GutiÚrrez-Ramos Chief Science Officer & Senior Vice President
Sadik Kassim Chief Technology Officer